Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs

Age (year) 60.8 ± 10.5
Proportion of female 83.0%
Disease duration (year) 10.0 (5.0–17.0)
BMI 22.8 ± 3.4
Average dose of prednisolone (mg) 0.0 (0.0–2.0)
CRP (mg/dL) 0.12 (0.03–0.38)
DAS28-CRP 2.39 (1.62–3.47)
SDAI 6.07 (2.35–14.32)
MHAQ 4.0 (0.0–10.0)
Duration of bDMARDs therapy 4.0 (3.0–6.0)
Type of anti-osteoporosis drugs PTH: 3.5%
Bisphosphonate: 47.1%
Others: 14.4%
None: 35.3%
Change of lumbar spine BMD/12 months (g/cm2) 0.004 (− 0.080 to 0.018)
Percent of least significant reduction of lumber spine BMD 13.1% (20/153)
Change of femoral neck BMD/12 months (g/cm2) − 0.001 (− 0.025 to 0.019)
Percent of least significant reduction of femoral neck BMD 34.0% (52/153)
  1. BMI body mass index, CRP serum C-reactive protein concentration, DAS28-CRP Disease Activity Score-28-CRP, SDAI simplified disease activity index, MHAQ modified Health assessment questionnaire, bDMARDs biologic disease-modifying anti-rheumatic drugs, PTH parathyroid hormone, BMD bone mineral density